Etrolizumab

Etrolizumab

  • August 2018 •
  • 31 pages •
  • Report ID: 5779812 •
  • Format: PDF
Drug Overview
Etrolizumab (Roche) is a humanized anti-beta7 integrin subunit monoclonal antibody. The drug was discovered by Genentech, which was acquired by Roche in 2009. Etrolizumab binds to the beta7 subunit of the alpha4-beta7 and alphaE-beta7 integrin heterodimers. This prevents the interaction of alpha 4-beta7 integrin with mucosal addressin cell adhesion molecule-1 and the interaction of alphaE-beta7 integrin with E-cadherin. In turn, this results in interference with immune cell trafficking into the intestine in a selective manner that avoids broad immunosuppression.
The drug is in late-phase development in Crohn’s disease and ulcerative colitis. The US Food and Drug Administration has granted orphan drug designation to etrolizumab for pediatric patients.